Maple Capital Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $241K | Sell |
480
-74
| -13% | -$35.5K | 0.01% | 108 |
|
|
2026
Q1 | $272K | Hold |
554
| – | – | 0.02% | 97 |
|
|
2025
Q4 | $321K | Buy |
554
+10
| +2% | +$5.66K | 0.02% | 96 |
|
|
2025
Q3 | $264K | Hold |
544
| – | – | 0.02% | 97 |
|
|
2025
Q2 | $221K | Sell |
544
-17
| -3% | -$7.11K | 0.02% | 109 |
|
|
2025
Q1 | $279K | Sell |
561
-53
| -9% | -$28.7K | 0.02% | 99 |
|
|
2024
Q4 | $319K | Sell |
614
-32
| -5% | -$17.6K | 0.02% | 93 |
|
|
2024
Q3 | $400K | Sell |
646
-39
| -6% | -$23.1K | 0.03% | 81 |
|
|
2024
Q2 | $379K | Buy |
685
+5
| +0.7% | +$2.86K | 0.03% | 87 |
|
|
2024
Q1 | $395K | Buy |
+680
| New | +$382K | 0.04% | 78 |
|
|
2022
Q1 | – | Sell |
-301
| Closed | -$201K | – | 111 |
|
|
2021
Q4 | $201K | Sell |
301
-225
| -43% | -$140K | 0.02% | 105 |
|
|
2021
Q3 | $301K | Hold |
526
| – | – | 0.04% | 84 |
|
|
2021
Q2 | $286K | Buy |
526
+17
| +3% | +$8.02K | 0.03% | 88 |
|
|
2021
Q1 | $232K | Buy |
509
+18
| +4% | +$8.59K | 0.03% | 89 |
|
|
2020
Q4 | $229K | Sell |
491
-4
| -0.8% | -$1.88K | 0.04% | 90 |
|
|
2020
Q3 | $242K | Sell |
495
-176
| -26% | -$72.7K | 0.04% | 93 |
|
|
2020
Q2 | $243K | Sell |
671
-644
| -49% | -$216K | 0.05% | 90 |
|
|
2020
Q1 | $373K | Sell |
1,315
-339
| -20% | -$107K | 0.09% | 71 |
|
|
2019
Q4 | $537K | Hold |
1,654
| – | – | 0.1% | 78 |
|
|
2019
Q3 | $482K | Sell |
1,654
-162
| -9% | -$46.4K | 0.1% | 77 |
|
|
2019
Q2 | $533K | Sell |
1,816
-678
| -27% | -$187K | 0.12% | 74 |
|
|
2019
Q1 | $683K | Sell |
2,494
-180
| -7% | -$44.8K | 0.16% | 62 |
|
|
2018
Q4 | $598K | Sell |
2,674
-25
| -0.9% | -$5.87K | 0.15% | 70 |
|
|
2018
Q3 | $659K | Sell |
2,699
-405
| -13% | -$93.2K | 0.15% | 73 |
|
|
2018
Q2 | $643K | Sell |
3,104
-800
| -20% | -$170K | 0.16% | 70 |
|
|
2018
Q1 | $806K | Buy |
3,904
+675
| +21% | +$142K | 0.2% | 69 |
|
|
2017
Q4 | $613K | Buy |
3,229
+450
| +16% | +$86.2K | 0.16% | 77 |
|
|
2017
Q3 | $526K | Buy |
2,779
+504
| +22% | +$91.3K | 0.14% | 78 |
|
|
2017
Q2 | $397K | Buy |
2,275
+138
| +6% | +$23.2K | 0.11% | 94 |
|
|
2017
Q1 | $328K | Buy |
2,137
+453
| +27% | +$69.2K | 0.1% | 109 |
|
|
2016
Q4 | $238K | Buy |
1,684
+290
| +21% | +$42.8K | 0.07% | 117 |
|
|
2016
Q3 | $222K | Buy |
+1,394
| New | +$215K | 0.07% | 118 |
|
Other funds holding TMO
Maple Capital Management's TMO Position: Q2 2026 in Review
Maple Capital Management reduced its Thermo Fisher Scientific (TMO) stake by 13% in Q2 2026, selling an estimated $35.5K and leaving 480 shares worth $241K. The position accounts for 0.01% of the portfolio, ranked #108.
Maple Capital Management first reported a position in TMO in Q3 2016 and has held it in 32 quarters since. The position peaked at $806K in Q1 2018. 2,620 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Maple Capital Management held 480 shares of Thermo Fisher Scientific worth $241K as of Q2 2026.
- Maple Capital Management sold 74 Thermo Fisher Scientific shares in Q2 2026, an estimated $35.5K.
- Thermo Fisher Scientific made up 0.01% of Maple Capital Management's portfolio in Q2 2026, its #108 holding.
- Maple Capital Management first reported a position in Thermo Fisher Scientific in Q3 2016 and has held it in 32 quarters since.
- Maple Capital Management's Thermo Fisher Scientific position peaked at $806K in Q1 2018.
- 2,620 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Maple Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.